CYBIN INC. CEO Michael Halstead will participate in a virtual fireside chat at the TD Cowen neuropsychiatry summit on September 23, 2026. Investors will be able to watch the webcast live, with a replay available through Helus Pharma’s Events & Presentations page after the session.
Key Highlights
- Michael Halstead will participate in the virtual summit session on September 23, 2026.
- The webcast will be available live, with a replay posted to the company’s Events & Presentations page.
- HLP003 is in Phase 3 development, while HLP004 is in Phase 2 development.
CYBIN INC. (NASDAQ: HELP) is a major pharmaceuticals company. Its commercial operating name, Helus Pharma, will have Chief Executive Officer Michael Halstead participate in a virtual fireside chat at the TD Cowen Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026.
CEO Appearance and Company Programs
The discussion will be webcast live, and a replay will remain available on Helus Pharma’s Events & Presentations page. CYBIN develops novel serotonergic agonists, which it describes as proprietary compounds designed to activate serotonin pathways. Its stated focus includes mental health conditions such as depression and anxiety. The company is developing HLP003 for adjunctive treatment of major depressive disorder and HLP004 for generalized anxiety disorder. CYBIN also says it maintains a wider research portfolio of investigational novel serotonergic agonists. The release contains forward-looking statements about the planned summit appearance and efforts involving drug discovery platforms, delivery systems, formulations and treatment regimens. The filing identifies potential risks including securities-market fluctuations, macroeconomic conditions, regulatory restrictions, disease outbreaks and the company’s ability to achieve its Business objectives.
FAQs
Q: When will the CYBIN INC. CEO speak at the TD Cowen summit?
A: Michael Halstead will participate in the virtual fireside chat on September 23, 2026. The session is part of the TD Cowen Annual Novel Mechanisms in Neuropsychiatry Summit.
Q: Where can investors watch the CYBIN INC. Webcast?
A: Investors can access the live webcast through the registration link provided by Helus Pharma. A replay will be available on the company’s Events & Presentations page.
Q: What programs is Helus Pharma developing?
A: Helus Pharma is developing HLP003 for adjunctive major depressive disorder treatment and HLP004 for generalized anxiety disorder. Both are proprietary novel serotonergic agonists.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.